Apixaban, empagliflozin, rivaroxaban and sacubitril/valsartan are just some of the medications included in this initial round of Medicare price negotiations. Their new prices were reduced by 56%, 66%, 62% and 53%, respectively. 

Jupiter Endovascular, a new subsidiary of Neptune Medical, aims to "bring the precision and control of direct surgical access to catheter-based interventions.”  

The FDA warned that the devices failed a safety inspection, but were still distributed for patient use. They have now all been located. 

The management of stable angina has been evolving at a rapid rate. Using a one-size-fits-all strategy is becoming a thing of the past, replaced by a patient-centered approach that requires open communication and a healthy understanding of recent clinical research.

A software update for the pump's mobile app was expected to fix ongoing battery issues, but the problem remains. 

The calcified plaque-shattering technology developed by Shockwave Medical continues to gain momentum. As more care teams start using IVL during PCI, researchers are paying close attention to its long-term impact on patient care.

A care team in Germany has completed what may be the first structural heart procedure of its kind on a high-risk patient. It started as a straightforward heterotopic caval valve implantation, but then paravalvular leak resulted in a change of plans. 

Physicians using the Paradise Ultrasound Renal Denervation system from Recor Medical or Symplicity Spyral Renal Denervation system from Medtronic will soon be eligible for a much more significant reimbursement when treating Medicare patients in an inpatient setting.